Followers | 134 |
Posts | 7040 |
Boards Moderated | 0 |
Alias Born | 02/09/2012 |
Monday, September 24, 2018 11:03:02 AM
3.5 MM shares sold at $86.50 a share...BUT...also gave each share an option to buy a share at equivalent of $ .15 a share.... therefore 7MM shares at equivalent $43.25 a share...
THIS IS GOING DOWN!!!
Recent ARGX News
- argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 05:00:00 AM
- argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease • GlobeNewswire Inc. • 04/16/2024 05:00:00 AM
- argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease • GlobeNewswire Inc. • 03/27/2024 06:00:00 AM
- argenx Announces Annual General Meeting of Shareholders on May 7, 2024 • GlobeNewswire Inc. • 03/26/2024 08:00:00 PM
- argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia • GlobeNewswire Inc. • 03/26/2024 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/08/2024 11:05:13 AM
- argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting • GlobeNewswire Inc. • 03/07/2024 09:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/29/2024 09:04:20 PM
- argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update • GlobeNewswire Inc. • 02/29/2024 06:00:00 AM
- argenx to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/26/2024 06:00:00 AM
- argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024 • GlobeNewswire Inc. • 02/22/2024 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/20/2024 11:06:40 AM
- argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy • GlobeNewswire Inc. • 02/20/2024 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/18/2024 11:10:34 AM
- argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis • GlobeNewswire Inc. • 01/18/2024 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/08/2024 11:06:54 AM
- argenx Highlights 2024 Strategic Priorities • GlobeNewswire Inc. • 01/08/2024 06:00:00 AM
- argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/02/2024 06:00:00 AM
- Argenx Down Nearly 26%, on Pace for Record Percent Decrease -- Data Talk • Dow Jones News • 12/20/2023 05:37:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/20/2023 11:00:20 AM
- argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus • GlobeNewswire Inc. • 12/20/2023 06:00:00 AM
- Argenx Down Over 10%, On Track for Largest Percent Decrease Since May 2022 -- Data Talk • Dow Jones News • 11/28/2023 04:16:00 PM
- Argenx Shares Down After Vyvgart Study Misses Primary Endpoint • Dow Jones News • 11/28/2023 12:03:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/28/2023 11:01:35 AM
- argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia • GlobeNewswire Inc. • 11/28/2023 06:00:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM